Abram Scientific announced it has secured $11.75 million in Series A financing to accelerate development of its proprietary portable coagulation diagnostics platform, CoagCare. The round was led by global pharmaceutical company Octapharma AG, with additional participation from existing and new investors affiliated with the University of Colorado Anschutz.
The funding will support continued development of the CoagCare system, advance key clinical milestones, and help position the platform for U.S. Food and Drug Administration 510(k) clearance. Abram Scientific is focused on next-generation coagulation diagnostics designed to improve patient care in bleeding disorders, trauma, and critical care medicine.
The CoagCare System is designed as a novel point-of-care meter that uses a single-use diagnostic test card. The platform employs proprietary technology to measure blood viscoelasticity and density, enabling characterization of the full coagulation cascade, from clot formation to fibrinolysis, in under 10 minutes. The system is intended to aid clinicians in evaluating blood clotting disorders and determining appropriate transfusions and therapies for patients undergoing trauma and surgical procedures.
According to the company, existing coagulation diagnostic platforms such as thromboelastography and thromboelastometry typically require 30 to 60 minutes for a complete measurement, including fibrinolysis. In contrast, CoagCare is designed to deliver a complete assessment from a single drop of blood in under 10 minutes. The portable, vibration-insensitive design is aimed at expanding use cases beyond traditional laboratory settings to remote and pre-hospital environments, including MEDEVAC helicopters and ambulances, where rapid transfusion decisions can be critical.
Octapharma’s investment marks its first major move into the diagnostics sector. The company, which develops and produces therapies from human plasma and human cell lines, views the investment as an opportunity to expand its presence across the continuum of care in hematology and critical care. The company said the partnership reflects its interest in emerging platforms that address unmet clinical needs in coagulation management.
Abram Scientific was founded by Dr. Abhishek Ramkumar, who serves as CEO and is the inventor of the CoagCare platform technology. The technology is protected by 17 U.S. and international granted patents, with additional applications currently under review. The CoagCare System has not yet received FDA clearance for marketing in the United States.
Octapharma is headquartered in Lachen, Switzerland, and employs more than 11,000 people, serving patients in 120 countries across immunotherapy, hematology, and critical care. The company operates seven R&D sites, five manufacturing facilities in Europe, and more than 195 plasma donation centers across the U.S. and Europe.
The University of Colorado Anschutz, a participant in the financing, is a major academic medical campus encompassing health professional schools, more than 60 centers and institutes, and two nationally ranked hospitals. The campus conducts research supported by $910 million in annual funding and is home to the CU Center of COMBAT Research, a key collaborator with Abram Scientific focused on military medical and trauma research.
KEY QUOTES:
“Our mission is to enable CoagCare to help adjudicate life-saving therapies and transfusions, so that the right therapy is provided to the patient at the right time and at the right dosage. Our collaboration with Octapharma and the University of Colorado provides both funding and strategic expertise, enabling us to move faster and smarter, and positioning CoagCare to revolutionize the current clinical paradigm.”
Abhishek Ramkumar, CEO, Founder, Abram Scientific
“We are excited to partner with Abram Scientific in this phase of next-generation technology development. Abram has a unique approach with real potential to reshape patient outcomes, and we are proud to accelerate their next stage of development. Abram’s CoagCare can empower clinicians to deliver goal-oriented therapy with greater accuracy, ensuring the right intervention, at the right time, in the right amount. This represents an important step forward in patient care and can help shape clinical guidelines nationally and globally.”
Flemming Nielsen, President, Octapharma USA, Inc.
“Uncontrolled hemorrhage remains one of the leading—and most preventable—causes of early trauma death. We are excited to partner with Abram Scientific to develop CoagCare to give surgeons and emergency physicians the critical information they need sooner to guide life-saving therapy decisions.”
Dr. Vik Bebarta, Endowed Chair in Emergency Medicine, University of Colorado Anschutz and Founding Director of The Center for COMBAT Research
